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ABSTRACT 
 
 Atherosclerosis, characterized by the build-up of cholesterol, immune cells and cellular 
debris within arterial walls, is accelerated following myocardial infarction by poorly understood 
mechanisms. Ubiquitin, a small, well-studied intracellular protein involved in protein turnover 
via the proteasome pathway, has recently been shown to exert extracellular effects on cardiac 
myocytes, in vitro, and in mice undergoing myocardial remodeling.  This study investigates the 
potential role of extracellular ubiquitin in atherosclerosis by determining its effects on two 
critical atherosclerotic processes: the migration of vascular smooth muscles cells and the uptake 
of modified LDL by monocyte/macrophages in foam cell formation. In the presence of ubiquitin, 
smooth muscle cell migration was accelerated and foam cell formation was enhanced, suggesting 
that ubiquitin has an active role in atherosclerosis. 
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BACKGROUND and INTRODUCTION 
Cardiovascular disease, commonly known as heart disease, is the leading cause of death 
in the United States. Approximately 600,000 individual deaths each year are associated with this 
disease, or roughly 25% of all associated deaths. One of the most common forms of this disease 
is coronary heart disease, a disease affecting the blood supply to cardiac tissue2. Atherosclerosis 
is the underlying mechanism that drives the progression of cardiovascular disease. Characterized 
as a chronic inflammatory disease, atherosclerosis is marked by the hardening and thickening of 
arterial walls due to a buildup of cellular debris within them, called plaque3. 
 
 
 
 
 
 
 
 
Atherosclerosis, in later stages of progression, can lead to major, life threatening clinical 
events, such as myocardial infarction (heart attack) and stroke3. When a plaque becomes large 
enough to rupture through the wall and into the vessel, thrombus (blood clotting) occurs around 
the ruptured plaque and blood flow can be reduced or possibly blocked completely by the 
Figure 1. Physiological representation of 
atherosclerosis. Atherosclerosis is generally 
known as the hardening of arterial walls due 
to plaque buildup. As seen left, normal flow is 
indicated in the top vessel, with little to no 
plaque buildup. The middle vessel shows an 
early stage atherosclerosis in which 
significant plaque buildup occurs, narrowing 
the arterial flow. The bottom vessel displays a 
ruptured plague resulting in a blood clot with 
blocked arterial flow, triggering myocardial 
infarction or stroke. (Image from Yeadon 
2015)1 
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thrombus, or at a location downstream if the clot breaks free in the blood. When blood flow is 
reduced or blocked in a specific area of the body, the potential for tissue damage and death rises 
dramatically.  
There are several cell types and biomolecules that are major components of 
atherosclerosis, including vascular smooth muscle cells, monocyte/macrophage cells, and low-
density lipoproteins. The arterial walls where atherosclerosis occurs are composed of vascular 
smooth muscles, not to be confused with cardiac myocytes, or cardiac muscle. Vascular smooth 
muscle cells comprise the deep muscular layer of the walls of arteries and vessels, which 
function to transport blood throughout the body. Monocytes are a specific type of leukocyte 
(white blood cell) that are major components of the body’s inflammatory immune response in 
plaque buildup4. Monocytes that are differentiated to uptake and digest foreign material and 
cellular debris are called macrophages. One other important component of atherosclerosis is low-
density lipoproteins or LDL. LDL is the major transportation molecule for cholesterol, which is 
incorporated into cell membranes and used for various biomolecular processes5. LDL, with 
bound cholesterol, is commonly referred to as “bad cholesterol”, as opposed to HDL (high-
density lipoprotein) “good cholesterol”, which is responsible for removal and recycling of 
cholesterol.  
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Figure 2. Atherosclerosis displayed in its entire pathophysiological progression. (A) Lesion formation represents early 
stages of disease. (B) Fatty streak represents foam cell formation. (C) Fibrous plaque represents necrotic death, plaque 
progression, and subsequent stabilization via vascular smooth muscle cell proliferation and migration. (D) Thrombosis 
indicates the potential risk of late stage atherosclerosis, which is plaque rupture and clotting, leading to myocardial 
infarction or stroke. (Image adapted from Steinl et al 2015)6 
 
 
The cellular mechanism of atherosclerosis involves many steps that are important to 
understanding the underlying pathophysiology of heart disease. In the first stages of 
atherosclerosis (Figure 2 – Lesion Initiation), an individual typically will have a higher than 
normal amount of cholesterol in the blood.  Derived from diet or endogenous synthesis, 
cholesterol is a major component of eukaryotic cellular membranes. Thus, it is understandable 
that the body has a need for large amounts of cholesterol. However, higher amounts of un-
utilized cholesterol in blood serum can lead to atherosclerosis. Cholesterol is transported through 
the body via blood by two major transport molecules, low-density lipoprotein (LDL) and high-
density lipoprotein (HDL), respectively referred to as “good” and “bad” cholesterol. These large 
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lipid rich transport proteins carry cholesterol through the body. LDL, or “bad” cholesterol, 
contains a higher amount of lipids such as cholesterol, while HDL or “good” cholesterol contains 
less lipid and more protein. LDL functions to deposit cholesterol in target tissue, and HDL, 
conversely, functions to remove cholesterol from a target tissue. Under normal physiological 
conditions, these processes are happening simultaneously and in a balanced manner as to not 
allow too much deposition or withdrawal. However, when LDL concentration is too high, 
atherosclerosis can occur.  
 When blood exits the heart and travels through the aorta, it encounters many branches or 
bifurcations, such as the coronary arteries. In these areas of bifurcation, the arterial flow is under 
high velocity and pressure. Due to not well understood pathophysiological reasons, these areas 
are more prone to be the site of atherosclerotic lesions than other areas, which explains why 
myocardial infarction is a major risk of late stage atherosclerosis7. High concentrations of LDL 
in the blood increases its likelihood of deposition in the arterial walls in areas of bifurcation, 
such as branching of the coronary artieries7. When this LDL is deposited into the walls, it can 
become modified, for example, by oxidation reactions via various free radicals in the intima of 
the wall or by local cell-mediated processes5. Once oxidized, LDL is extremely difficult to 
remove. Recognizing an increase in oxidized LDL (oxLDL) as a “foreign” presence, local tissue 
will begin secreting signaling molecules called cytokines5 (Figure 2 – Fatty Streak). Cytokines 
are specialized to activate and trigger an inflammatory immune response. These cytokines will 
activate leukocytes in the blood, specifically monocytes, to migrate into the arterial walls at the 
affected area4.  Once in the wall, monocytes will differentiate into macrophages, specialized 
scavenger immune cells designed to ingest foreign material invading in the body.  The 
macrophages ingest the oxLDL for metabolic processing and removal. The processing of oxLDL 
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involves the disassembly of the LDL particles and storage of the cholesterol as cholesterol esters 
in lipid-rich droplets inside the cell4.  The continued uptake of oxLDL leads to accumulation of 
these lipid-rich droplets within the macrophage resulting in them becoming “foam cells” due to 
their foamy appearance when viewed under light microscopy compared to surrounding tissue. 
Foam cell formation is considered by most to be the hallmark of atherosclerosis3-5, 7. If the rate of 
LDL deposition and subsequent oxidation is happening to such as large degree that the HDL in 
local tissue cannot respond adequately to the demand for removal of cholesterol, the 
inflammation continues with more recruitment of monocytes to the area which subsequently 
become foam cells. This accumulation of foam cells results in the formation of “fatty streaks” 
along the vessel wall and is the first visible stage of plaque formation.  
Physiologically, the local tissue goes a step further to help attenuate this process (Figure 
2 – Fibrous Plaque). At a certain point, foam cells will actually loose viability and die, unable to 
meet the demand for oxLDL removal. This can occur via apoptosis, which is a programmed cell 
death in which internal contents are digested and packaged for surrounding tissue to ingest8. 
Important to note that this does not cause any further damage to surrounding cells. However, cell 
death can also occur dramatically in the form of necrosis, which is simply the bursting of a cell 
and the release of all its contents into local interstitial space due to overwhelming stress. This 
process is dangerous for local tissue as it can cause further inflammation in the tissue8. Foam cell 
death in atherosclerosis occurs both ways. Necrotic death of foam cells is thought to be another 
contributing mechanism behind the oxidation of native LDL to oxLDL, which can further 
accelerate the inflammatory response and atherosclerosis5. Foam cell death can lead to large 
necrotic and fatty debris concentrations in the arterial wall. The local tissue will then begin 
stabilizing the debris, or plaque, by recruiting vascular smooth muscle cells (VSMC) in the wall 
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to proliferate and migrate over the plaque and secrete an extracellular matrix to form a fibrous 
cap over the plaque9. VSMC migration occurs throughout later stages of atherosclerosis and is a 
critical component of the formation of a stable plaque. The fibrous-rich extracellular matrix 
secreted by the VSMC functions to attenuate further plaque buildup and provide a barrier 
between the highly thrombogenic molecules in the necrotic plaque and clotting factors in the 
blood9.  
Atherosclerosis will continue to progress as long as the deposition of LDL in the artery 
wall stimulates the inflammatory response. If the fibrous cap erodes, the plaque may rupture 
through the arterial wall into the blood stream (Figure 2 – Thrombosis). When this happens, 
thrombus formation is triggered via activation of platelets in the serum10. This rupture and 
subsequent clot formation can either reduce or block flow in the immediate vessel. If flow is 
blocked, downstream tissue death occurs as blood supply is completely stopped. If this occurs in 
the coronary arteries, a myocardial infarction (heart attack) occurs and clots that break loose can 
travel to the brain and cause a stroke. A myocardial infarction increases the risk for additional 
MI’s due to acceleration of the atherosclerotic process, at least partly due to stimulation of the 
inflammatory responses driving plaque progression 11. Overall, atherosclerosis is best understood 
to be an inflammatory process designed to attenuate LDL deposition in arterial walls and to 
stabilize plaques against rupture.  
 
Ubiquitin, as its name implies, is a universally present protein of approximately 8.5 kDa 
found in all eukaryotic cells. It is highly conserved, fluctuating on average by only 2-3 amino 
acid residues across all known species. Ubiquitin plays a well-known role intracellularly in the 
post-translational modification of proteins12. In common cellular processes, such as protein 
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turnover and apoptosis, ubiquitinylation is utilized as a tag for protein degradation by the 
proteasome pathway. 
 
 
Figure 3. Ubiquitin is a highly conserved protein with well-studied intracellular 
function in the post-translational protein modification process, but its 
extracellular function is not well understood. Above is 3D model of ubiquitin. 
(Image adapted from Ramage et al 1994)13 
 
 
 
 
Extracellularly, however, ubiquitin’s role is poorly understood. It is known to be present 
in serum, cerebral spinal fluid, and urine under normal physiological conditions 14. However, the 
finding that extracellular levels of ubiquitin increase during some disease states has led to more 
recent investigations into its extracellular function. In patients that have suffered an acute 
myocardial infarction, serum ubiquitin concentrations were found to be increased threefold 15. 
Using this as a basis, another study showed that ubiquitin was an active modulator of myocardial 
remodeling, the process by which cardiac tissue adapts following a myocardial infarction 12, 16.   
Although the involvement of ubiquitin in modulating atherosclerosis is unknown, several lines of 
evidence suggest a potential function of ubiquitin in either the initiation and/or progression of 
plaque formation.  Ubiquitin binds with specificity to a G-protein coupled surface receptor, CXC 
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Chemokine Receptor 4, (CXCR4) 17 in a manner similar to a typical chemokine interaction, 
suggesting a potential mediator of ubiquitin signaling 18.  Primary human leukocytes (the 
monocytes active in foam cell formation) and human vascular smooth muscle cells,  both express 
the CXCR4 receptor 19. Studies conducted in mouse models have shown that CXCR4 and its 
chemokine ligand, CXCL12, function in the initiation and progression of atherosclerosis20, 21.     
 
Figure 4. Ubiquitin has been demonstrated and investigated to confirm its specific receptor binding characteristics 
with C-X-C Chemokine Receptor 4, commonly referred to as CXCR4. Above is a representation of Ubiquitin 
interacting with the CXCR4 receptor. (Image adapted from Saini et al 2011)18 
 
 
Thus, we hypothesize that ubiquitin signaling plays a role in atherosclerosis and to begin 
to test this hypothesis, we proposed the following two aims: 
 
AIM 1: To examine the potential role of ubiquitin in the initiation of atherosclerosis by evaluating 
the effect of exogenous ubiquitin on monocyte/macrophage foam cell formation in vitro. 
 
AIM 2: To examine the potential role of ubiquitin in the progression of atherosclerosis by 
determining the effect of exogenous ubiquitin on the migration of vascular smooth muscle cells 
in vitro.  
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METHODS AND MATERIALS 
 
Foam Cell Assay: 
 
RAW264.7 cells, a murine monocyte/macrophage cell line, were purchased from 
American Type Culture Collection (ATCC, VA, USA). Cells were plated on 35mm tissue culture 
plates at a density of 200,000 cells/mL, in standard growth media (Dulbecco’s Modified Eagle’s 
Media, containing 10% fetal bovine serum, 100 U/ml penicillin and 100 µg/ml streptomycin).  
All cells were incubated at 37°C in 10% CO2 / 95% air humidified atmosphere.  Cells were 
grown overnight to ~50% confluence and then divided into four groups as follows: Control (-
oxLDL/-ubiquitin), Baseline (+ 50 µg/ml oxLDL), Ubiquitin 10 (10 µg/mL ubiquitin + 50 µg/ml 
oxLDL), and Ubiquitin 20 (20 µg/mL ubiquitin + 50 µg/ml oxLDL).  The cells were serum 
starved for 24hr prior to treatments.  Ubiquitin (BostonBiochem, Cambridge, MA) was added 
from 100 µg/ml stock solutions made in sterile phosphate buffered saline (PBS) one hour prior to 
addition of oxLDL (Alfa Aesar, Ward Hill, MA) from 2 mg/ml stock solutions. After 24 hours, 
cells were fixed in 10% buffered formalin solution, rinsed with PBS and stained with Oil-Red-O, 
a dye for intracellular neutral lipids22.  Lipid droplet formation was examined using a model 
BX41 Olympus light microscope equipped with a Micropublisher 5.0 cooled RTV digital camera 
(Qimaging). The percent of Oil-red O positive cells in photomicrographs was determined by 
counting four randomly selected fields of 10x magnification (~200 total cells/field) for each 
treatment. Statistical differences were determined by 2-tailed, unpaired Student t-test using 
SigmaPlot software (SPSS Inc.) with P<0.05 considered statistically significant. 
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Smooth Muscle Cell Migration (Scratch) Assay: 
 
MOVAS-1 cells (a transformed murine vascular aortic smooth muscle cell line) were 
purchased from the American Type Culture Collection (ATCC, VA, USA) and maintained in 
modified DMEM (ATCC #30-2002) containing 4.5 g/L D-Glucose, 1.5 g/L sodium bicarbonate 
and supplemented with 10% FBS, 0.2 mg/ml G-418, 100U/ml penicillin, and 100 µg/ml 
streptomycin in a 10% CO2 / 95% air humidified atmosphere.  Cells were plated on 35mm tissue 
culture plates at a density of 200,000 cells/plate and cultured in standard growth media until they 
formed a confluent monolayer.  The plates were divided into three groups and ubiquitin added as 
follows: Control (no ubiquitin), Ubiquitin 10 (10 µg/mL ubiquitin), and Ubiquitin 20 (20 µg/mL 
ubiquitin) ubiquitin. Following 24hr in the presence of ubiquitin, a sterile pipette tip was used to 
make a scratch of uniform width across the cell monolayer on each plate.  Each scratch was 
digitally documented using a model BX41 Olympus light microscope equipped with a 
Micropublisher 5.0 cooled RTV digital camera (Qimaging).  The cells were incubated for 
another 12h prior to a second digital photograph.  The width of each scratch at time 0h and time 
12h was measured at six different points along the length of the scratch using computer-assisted 
morphometric analysis (ImageJ, NIH, Bethesda, MD).  The migration distance was calculated by 
subtracting the mean width of a scratch at time 0h from the mean width recorded at time 12h, 
divided by two.  Statistical differences were determined by 2-tailed, unpaired Student t-test using 
SigmaPlot software (SPSS Inc) with P<0.05 considered statistically significant. 
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RESULTS 
The hallmark of early atherosclerosis is the formation of macrophage-derived foam cells.  
Cultured macrophages can take on a foam cell phenotype when they ingest oxLDL via receptor-
mediated mechanisms and store the oxLDL-derived cholesterol as cholesteryl esters in lipid 
droplets.  To assess the effect of extracellular ubiquitin on foam cell formation in vitro, we 
stained oxLDL-treated RAW264.7 macrophages that had been cultured in the presence and 
absence of ubiquitin with Oil-Red-O, a dye selective for intracellular neutral lipids as shown in 
Figure 6.  Lipid droplet formation in the cytosol was undetectable by Oil-Red-O staining of 
RAW264.7 macrophages cultured in the absence of oxLDL (Figure 6A) but readily detectable in 
macrophages cultured for 24hr in media containing 50 µg/ml oxLDL (Figure 6B).  Culturing of 
RAW264.7 cells with oxLDL in the presence of increasing concentrations of ubiquitin resulted 
in dose-dependent increases in the accumulation of cytosolic lipid droplets (Figure 6C, D). 
Quantitation of the percent of cells containing lipid droplets under each condition revealed that 
treatment with 20 µg/ml ubiquitin resulted in a significant (~1.6 fold) increase in the percent of 
cells containing lipid droplets compared to baseline controls (Figure 7). 
 
 
 
Figure 5. Foam cell formation assay timeline. Cells are serum starved 24hr prior to ubiquitin/oxLDL treatment. 
Ubiquitin treatment sets received supplementation 1hr prior to addition of oxLDL to maximize the effect, if any, 
exerted during oxLDL loading. After 24hr, the cells were fixed and stained with Oil-Red-O. 
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Figure 6. Representative photomicrographs of Oil-Red-O stained RAW 264.7 macrophages cultured in the presence 
and absence of oxLDL and ubiquitin. Panel A) Control cells cultured in absence of oxLDL. Panel B) Baseline Cells 
cultured in the presence of 50 µg/mL oxLDL. Panels C and D) Ubiquitin 10 and Ubiquitin 20 Cells cultured in the 
presence of 50 µg/mL oxLDL and 10 or 20 µg/mL ubiquitin, respectively. (Magnification 10x) 
 
 
Figure 7. Effect of ubiquitin on RAW 264.7 macrophage foam cell formation. Quantification of the percent of cells 
positive for Oil-Red-O staining after 24hr in media supplemented with oxLDL and 0, 10 or 20 µg/mL ubiquitin as 
indicated. Cells were considered positive if any Oil-Red-O staining was present inside cell, and negative if no 
staining was visible. * indicates p<0.05 
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To investigate the effect of ubiquitin on VSMC migration a “scratch” test was performed. 
A “scratch” test involves scratching a monolayer of cells to create a gap between two cell edges, 
and then measuring the width of the gap over a determined period of time. For this study, a 12-
hour migration rate of MOVAS-1 cells, a murine vascular aortic smooth muscle cell line, was the 
primary focus (Figure 8). Cells were cultured in varying amounts of ubiquitin and scratched to 
create a gap in the monolayer of cells. Images were taken initially and 12hr later to measure the 
change in gap width over time. Figure 9 shows a representative scratch test assay of MOVAS-1 
cells in the absence and presence of ubiquitin. Migration distance of MOVAS-1 cells cultured in 
the absence of ubiquitin was used as a control (Figure 9A). Cells treated with 10 µg/mL 
ubiquitin exhibited an increased migration distance compared to the control group (Figure 9B). 
In the presence of 20 µg/mL ubiquitin, MOVAS-1 cells showed an enhanced migration 
compared to control cells (Figure 9C). Quantitation revealed that treatment with 20 µg/mL 
ubiquitin resulted in a statistically significant (~15%) increase in the mean migration distance 
when compared to controls in the absence of ubiquitin (Figure 10 + 11).  
 
 
 
Figure 8. Smooth muscle cell scratch test timeline. Monolayers are treated with ubiquitin 24hr prior to the initial 
scratch and images captured. Images are captured again after 12hr for final measurements of migration. 
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Figure 9. Effect of ubiquitin on migration of MOVAS-1 cells as determined by scratch assay. Representative images 
caputred of time 0hr and time 12hr of a scratch test assay. Treatments were introduced 24hr prior to initial 0hr 
scratch and were as follows: (A) Control, (B) 10 µg/mL ubiquitin, and (C) 20 µg/mL ubiquitin. Yellow dashed lines 
indicate the margins of the gap in the monolayers. (Magnification 10x).
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A – 12 Hour Scratch
 
 
B – 12 Hour Scratch   
 
 
 
Figure 10.  Quantitation of the migration of MOVAS-1 cells in the presence of varying amounts of extracellular 
ubiquitin. A and B show the results from two independent assays, and performed in triplicate. Treatment sets were 
done 24hr prior to initial scratch and were as follows: Control, 10 µg/mL ubiquitin, and 20 µg/mL ubiquitin.  
 
 
 
Figure 11. Effect of ubiquitin on MOVAS-1 cell migration expressed as percent of control mean. Smooth muscle cell 
migration was studied using a scratch test assay of MOVAS-1 cell line as described in methods. Treatments were 
introduced 24hr prior to initial scratch and were as follows: Control, 10 µg/mL ubiquitin, and 20 µg/mL ubiquitin. * 
indicates p<0.05 versus control 
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DISCUSSION 
 
 To investigate the role of extracellular ubiquitin on atherosclerosis, these in vitro studies 
measured the effects of ubiquitin supplementation on two major processes associated with 
atherosclerosis: 1) foam cell formation and 2) smooth muscle cell migration. Foam cell 
formation is an early event in atherosclerosis and considered the hallmark of atherosclerosis, 
while smooth muscle cell migration is a vital process in later stages that functions to stabilize 
plaque. Ubiquitin’s role in these processes is not known; however, with recent discoveries of 
ubiquitin specific receptor binding to CXCR417, 19, known elevated serum ubiquitin levels 
following myocardial infarction15, and demonstrated attenuating effects in myocardial 
remodeling16, suggests ubiquitin potentially plays a signaling role in atherosclerosis. 
In both the foam cell formation and smooth muscle cell migration, statistically significant 
results were found when ubiquitin was introduced. Foam cell formation resulting from the uptake 
of oxLDL was increased as the concentration of extracellular ubiquitin increased from 10 to 20 
µg/mL, with a statistically significant enhancement of Oil-Red-O positive staining in RAW 
264.7 cells treated with 20 µg/mL ubiquitin, indicating an increase in foam cell formation by 
ubiquitin. This was graphically represented in Figure 7. This result suggests that ubiquitin may 
play a role in early atherosclerosis by enhancing oxLDL uptake via macrophage foam cell 
formation. This effect of ubiquitin may provide an explanation for why myocardial infarction 
accelerates subsequent atherosclerosis.  
 Smooth muscle cell migration was accelerated in the presence of increasing amounts of 
extracellular ubiquitin, with a statistically significant acceleration of MOVAS-1 migration in 
cells treated with 20 µg/mL ubiquitin. This was represented by Figure 11, showing the increase 
in migration distance in 12hr periods for respective concentrations of ubiquitin. These data 
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suggest that ubiquitin may affect later stages of atherosclerosis by altering SMC migration 
during plaque stabilization, a key factor in preventing rupture and subsequent myocardial 
infarction or stroke. 
 Previous studies found that serum ubiquitin levels were increased in some diseased states, 
yet increased levels do not necessarily indicate actual involvement. Other studies in mice models 
reveal ubiquitin plays a modulating role in myocardial remodeling, but the mechanism by which 
it occurs is still unknown. This study found that the presence of ubiquitin plays a role in 
atherosclerotic processes in vitro, as foam cell formation was enhanced and smooth muscle cell 
migration accelerated. However, whether ubiquitin alters atherosclerosis in vivo and by what 
mechanism remains to be investigated. 
 Future studies to evaluate ubiquitin’s role in atherosclerosis, and specifically the two 
associated processes studied here, should include determining if the enhancement of foam cell 
formation and acceleration of VSMC migration are due to ubiquitin-CXCR4 receptor interaction. 
To confirm that these effects are modulated and controlled through the CXCR4 receptor, a 
CXCR4 antagonist could be employed to block any effect of the CXCR4 receptor. If the 
observed effects of ubiquitin are muted in the presence of CXCR4 antagonism, it would suggest 
that ubiquitin acts as a modulator to these processes through the CXCR4 receptor. Other means 
to gain better insight into ubiquitin’s role in atherosclerosis would be to do assays on primary 
monocyte/macrophage and vascular smooth muscle cell types rather than cell lines, which would 
behave more similar to in vivo environments. Even further, to investigate its role more 
effectively, studies done on primary human monocyte/macrophage and vascular smooth muscle 
cell types would more accurately model the human atherosclerotic process in vitro. Finally, in 
vivo studies using murine models of atherosclerosis to investigate ubiquitin’s role in 
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atherosclerosis would be warranted. Results from such studies would then serve as the 
foundation for additional research aimed at developing ubiquitin based therapies for the 
treatment of atherosclerosis in humans.  
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